Immunic (NASDAQ:IMUX) Lowered to “Sell” Rating by StockNews.com

StockNews.com cut shares of Immunic (NASDAQ:IMUX) from a hold rating to a sell rating in a report issued on Saturday morning.

A number of other equities research analysts also recently issued reports on the stock. D. Boral Capital reissued a “buy” rating and set a $17.00 price objective on shares of Immunic in a research report on Thursday. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Immunic in a research report on Friday. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $12.67.

Immunic Trading Up 6.6 %

IMUX opened at $1.26 on Friday. Immunic has a 12-month low of $0.92 and a 12-month high of $2.11. The company has a market cap of $113.32 million, a price-to-earnings ratio of -1.02 and a beta of 1.87. The company’s 50 day moving average is $1.02 and its 200 day moving average is $1.26.

Institutional Investors Weigh In On Immunic

Institutional investors have recently bought and sold shares of the business. Invesco Ltd. purchased a new position in shares of Immunic in the fourth quarter valued at about $37,000. Virtu Financial LLC bought a new stake in Immunic during the 3rd quarter valued at approximately $50,000. HB Wealth Management LLC purchased a new position in Immunic in the 4th quarter worth approximately $81,000. Barclays PLC bought a new position in Immunic in the 4th quarter worth approximately $84,000. Finally, Jane Street Group LLC grew its holdings in Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after buying an additional 38,553 shares in the last quarter. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.